Cargando…
Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis
Diffuse alveolar hemorrhage (DAH) is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is used to treat bleeding in patients with hemophilia and antibodies to factor VIII or IX. It is increasingly being used in lif...
Autores principales: | Khoulani, Dania, Rao, Bharat, Khanshour, Ammar, Kuriakose, Philip, Yessayan, Lenar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119916/ https://www.ncbi.nlm.nih.gov/pubmed/25114814 http://dx.doi.org/10.1155/2014/283086 |
Ejemplares similares
-
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis
por: Mandal, S. K., et al.
Publicado: (2012) -
Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage
por: Heslet, Lars, et al.
Publicado: (2006) -
Cryoglobulinemic vasculitis with blood schistocytosis and bone marrow vasculitis
por: Jasim, Afreen, et al.
Publicado: (2023) -
Potential effect of Sildenafil beyond pulmonary hypertension in a patient with diffuse systemic sclerosis and cryoglobulinemic vasculitis
por: Gheita, Tamer A, et al.
Publicado: (2014) -
Infective Endocarditis Observed With Cryoglobulinemic Vasculitis
por: Liu, Kevin, et al.
Publicado: (2020)